Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
PLoS One ; 11(9): e0161779, 2016.
Article in English | MEDLINE | ID: mdl-27610613

ABSTRACT

The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with metastatic melanoma (CHECKMATE-067). Here we describe the preclinical development strategy that predicted these clinical results. Synergistic antitumor activity in mouse MC38 and CT26 colorectal tumor models was observed with concurrent, but not sequential CTLA-4 and PD-1 blockade. Significant antitumor activity was maintained using a fixed dose of anti-CTLA-4 antibody with decreasing doses of anti-PD-1 antibody in the MC38 model. Immunohistochemical and flow cytometric analyses confirmed that CD3+ T cells accumulated at the tumor margin and infiltrated the tumor mass in response to the combination therapy, resulting in favorable effector and regulatory T-cell ratios, increased pro-inflammatory cytokine secretion, and activation of tumor-specific T cells. Similarly, in vitro studies with combined ipilimumab and nivolumab showed enhanced cytokine secretion in superantigen stimulation of human peripheral blood lymphocytes and in mixed lymphocyte response assays. In a cynomolgus macaque toxicology study, dose-dependent immune-related gastrointestinal inflammation was observed with the combination therapy; this response had not been observed in previous single agent cynomolgus studies. Together, these in vitro assays and in vivo models comprise a preclinical strategy for the identification and development of highly effective antitumor combination immunotherapies.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunotherapy , Melanoma/drug therapy , Animals , Antibodies, Monoclonal/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , CTLA-4 Antigen/antagonists & inhibitors , CTLA-4 Antigen/metabolism , Cell Line, Tumor , Cells, Cultured , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/therapy , Combined Modality Therapy , Disease Models, Animal , Female , Humans , Ipilimumab , Lymphocytes/immunology , Lymphocytes/metabolism , Macaca fascicularis , Melanoma/metabolism , Melanoma/therapy , Mice , Mice, Inbred C57BL , Nivolumab , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/metabolism , T-Lymphocytes, Regulatory/metabolism
3.
J Exp Med ; 206(2): 275-85, 2009 Feb 16.
Article in English | MEDLINE | ID: mdl-19171767

ABSTRACT

CD4(+) recent thymic emigrants (RTEs) comprise a clinically and immunologically important T cell population that indicates thymic output and that is essential for maintaining a diverse alphabeta-T cell receptor (TCR) repertoire of the naive CD4(+) T cell compartment. However, their frequency and function are poorly understood because no known surface markers distinguish them from older non-RTE naive CD4(+) T cells. We demonstrate that protein tyrosine kinase 7 (PTK7) is a novel marker for human CD4(+) RTEs. Consistent with their recent thymic origin, human PTK7(+) RTEs contained higher levels of signal joint TCR gene excision circles and were more responsive to interleukin (IL)-7 compared with PTK7(-) naive CD4(+) T cells, and rapidly decreased after complete thymectomy. Importantly, CD4(+) RTEs proliferated less and produced less IL-2 and interferon-gamma than PTK7(-) naive CD4(+) T cells after alphabeta-TCR/CD3 and CD28 engagement. This immaturity in CD4(+) RTE effector function may contribute to the reduced CD4(+) T cell immunity observed in contexts in which CD4(+) RTEs predominate, such as in the fetus and neonate or after immune reconstitution. The ability to identify viable CD4(+) RTEs by PTK7 staining should be useful for monitoring thymic output in both healthy individuals and in patients with genetic or acquired CD4(+) T cell immunodeficiencies.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cell Adhesion Molecules/metabolism , Cell Movement/immunology , Immunity, Cellular/immunology , Receptor Protein-Tyrosine Kinases/metabolism , Thymus Gland/immunology , Age Factors , Animals , Biomarkers , CD4-Positive T-Lymphocytes/metabolism , CHO Cells , Cricetinae , Cricetulus , DNA Primers/genetics , Flow Cytometry , Humans , Immunophenotyping , Thymus Gland/cytology
4.
Proc Natl Acad Sci U S A ; 99(5): 3007-12, 2002 Mar 05.
Article in English | MEDLINE | ID: mdl-11867763

ABSTRACT

Studies presented here show that the expression of CD4, MHC class II (Ia,) and B220 cleanly resolves a major and a minor subset within the earliest pro-B cell population (germ-line pro-B) in adult bone marrow (BM). The major subset expresses intermediate B220 and low CD4 levels. The minor subset, which constitutes roughly 20% of the adult germ-line pro-B, expresses very low B220 levels and does not express CD4. Ia is clearly detectable at low levels on the major germ-line pro-B subset, both in wild-type adult mice and in gene-targeted mice (RAG2-/- and microMT), in which B cell development terminates before the pre-B cell stage. A small proportion of cells in the more mature pro-B cell subsets (Hardy Fractions B and C) also express Ia at this level. In contrast, Ia levels on the minor subset are barely above (or equal to) background. Surprisingly, the major germ-line pro-B cell subset found in adults is missing in fetal and neonatal animals. All of the germ-line pro-B in these immature animals express a phenotype (very low B220, no CD4, or Ia) similar to that of the minor pro-B cell subset in adult BM. Because B cell development in fetal/neonatal animals principally results in B-1 cells, these findings demonstrate that the B-1 development pathway does not include the major germ-line pro-B subset found in adult BM and hence identify a very early difference between the B-1 and -2 development pathways.


Subject(s)
B-Lymphocyte Subsets/cytology , Hematopoietic Stem Cells/cytology , Animals , Animals, Newborn , B-Lymphocyte Subsets/classification , B-Lymphocyte Subsets/immunology , Bone Marrow Cells/classification , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , CD4 Antigens/biosynthesis , Cell Differentiation , Hematopoietic Stem Cells/classification , Hematopoietic Stem Cells/immunology , Histocompatibility Antigens Class II , Leukocyte Common Antigens/biosynthesis , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic
5.
J Biol Chem ; 277(9): 7386-95, 2002 Mar 01.
Article in English | MEDLINE | ID: mdl-11751888

ABSTRACT

We observed that the human CD40 ligand (CD40L) gene 5'-flanking region conferred weak promoter activity in activated CD4 T cells, suggesting that additional regions are required for optimal CD40L gene transcription. We therefore examined a 3'-flanking segment of the CD40L gene, which contained a putative NF-kappaB/Rel cis-element, for its ability to enhance CD40L promoter function. This segment augmented CD40L promoter activity in an orientation-independent manner in CD4 T-lineage cells but not in human B cell or monocyte cell lines. Mapping of CD4 T-lineage cell nuclei identified a DNase I-hypersensitive site in the flanking region near the NF-kappaB/Rel sequence, suggesting a transcriptional regulatory role. This was further supported by truncation analysis and site-directed mutagenesis, which indicated that the CD40L 3'-flanking NF-kappaB/Rel cis-element was critical for enhancer function. Electrophoretic mobility shift assays showed that the cis-element preferentially bound the p50 form of the NF-kappaB1 gene contained in human T cell nuclear protein extracts. This binding also appeared to occur in vivo in CD4 T cells based on chromatin immunoprecipitation assays using NF-kappaB p50-specific antiserum. Together, these results suggest that the CD40L gene 3'-flanking region acts as a T cell-specific classical transcriptional enhancer by a NF-kappaB p50-dependent mechanism.


Subject(s)
CD40 Ligand/metabolism , Promoter Regions, Genetic , T-Lymphocytes/metabolism , Transcription, Genetic , B-Lymphocytes , Base Sequence , Binding Sites , Binding, Competitive , CD4 Antigens/biosynthesis , Cell Line , Cell Nucleus/metabolism , DNA/metabolism , DNA, Complementary/metabolism , Deoxyribonuclease I/metabolism , Dose-Response Relationship, Drug , Enhancer Elements, Genetic , Genes, Reporter , Humans , Interleukin-2/metabolism , Jurkat Cells , Models, Genetic , Molecular Sequence Data , Monocytes/metabolism , Mutagenesis, Site-Directed , NF-kappa B/chemistry , NF-kappa B/metabolism , NF-kappa B p50 Subunit , Plasmids/metabolism , Precipitin Tests , Protein Binding , Proto-Oncogene Proteins c-rel/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...